Celgene acquiring Delinia

Celgene Corp. (NASDAQ:CELG) will acquire autoimmune company Delinia Inc. (Cambridge, Mass.) for $300 million up front. Delinia shareholders are also eligible for $475 million in milestones tied to the biotech's lead candidate, DEL106.

Celgene expects to begin clinical testing next year of DEL106, a Treg-selective IL-2 receptor agonist (see BioCentury Innovations, Oct. 13, 2016)...